ZHONGSHENGYAOYE(SZ:002317) Xin Lang Cai Jing·2025-07-17 00:32Core Viewpoint - The company expects a significant increase in net profit for the first half of 2025, driven by reduced non-recurring factors and the approval of new drugs [1][2]. Group 1: Financial Performance - The company anticipates a net profit of 170 to 210 million yuan for the first half of 2025, representing a year-on-year growth of 94.49% to 140.25%, primarily due to the diminishing impact of non-recurring gains from 2024 [2]. - The expected growth in net profit excluding non-recurring items is projected to be between 3.64% and 26.67% [2]. - Revenue forecasts for 2025 to 2027 are estimated at 2.712 billion, 2.997 billion, and 3.290 billion yuan, respectively, with corresponding EPS of 0.39, 0.49, and 0.60 yuan [4]. Group 2: Product Development - The company has received approval for its innovative drug, Angladiwe, which is the world's first RNA polymerase PB2 protein inhibitor for influenza, expected to contribute to future growth [2]. - Angladiwe is the only anti-influenza drug in China that has undergone head-to-head phase III clinical trials with Oseltamivir, showing a nearly 10% reduction in median time to fever relief compared to Oseltamivir [2]. - The company is rapidly advancing its GLP-1/GIP dual receptor agonist, RAY1225, which has shown promising results in weight loss and metabolic improvement, with ongoing phase III clinical trials in China [3]. Group 3: Market Potential - RAY1225 has potential for international licensing and is positioned to compete effectively in the market, with a higher weight loss achievement rate compared to existing treatments [3][4]. - The company plans to participate in the 2025 medical insurance negotiations for Angladiwe, and is also developing a pediatric formulation of the drug, which has shown favorable results in phase II clinical trials [2].